Editorial: rifaximin in cirrhosis-is this what we've been waiting for? Authors' reply

S H Kang^{1

2}, Y B Lee³, J-H Lee¹

Affiliations

¹ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
² Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
³ Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

Editorial

S H Kang et al. Aliment Pharmacol Ther. 2017 Nov.

. 2017 Nov;46(10):1017-1018.

doi: 10.1111/apt.14343.

S H Kang^{1

2}, Y B Lee³, J-H Lee¹

¹ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
² Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
³ Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

No abstract available

Comment on

Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH, Lee YB, Lee JH, Nam JY, Chang Y, Cho H, Yoo JJ, Cho YY, Cho EJ, Yu SJ, Kim MY, Kim YJ, Baik SK, Yoon JH. Kang SH, et al. Aliment Pharmacol Ther. 2017 Nov;46(9):845-855. doi: 10.1111/apt.14275. Epub 2017 Aug 24. Aliment Pharmacol Ther. 2017. PMID: 28836723
Editorial: rifaximin in cirrhosis - is it what we've been waiting for?
Huang J. Huang J. Aliment Pharmacol Ther. 2017 Nov;46(10):1016-1017. doi: 10.1111/apt.14325. Aliment Pharmacol Ther. 2017. PMID: 29052858 No abstract available.